Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 1
2004 2
2006 3
2007 1
2008 2
2009 2
2010 1
2011 1
2015 2
2017 1
2018 1
2019 1
2020 1
2021 2
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F; RAISE Study Investigators. Tabernero J, et al. Lancet Oncol. 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Epub 2015 Apr 12. Lancet Oncol. 2015. PMID: 25877855 Clinical Trial.
Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer.
Detert Oude Weme SEH, Hulskotte LMG, Vervenne WL, Imholz ALT, Cremers RGHM, Taxis K, Reyners AKL, van Berlo-van de Laar IRF, Jansman FGA, Benoist GE. Detert Oude Weme SEH, et al. Among authors: vervenne wl. Clin Pharmacokinet. 2023 Jul;62(7):989-996. doi: 10.1007/s40262-023-01255-1. Epub 2023 May 10. Clin Pharmacokinet. 2023. PMID: 37162620 Free PMC article.
Systemic treatment of oesophageal cancer.
Richel DJ, Vervenne WL. Richel DJ, et al. Among authors: vervenne wl. Eur J Gastroenterol Hepatol. 2004 Mar;16(3):249-54. doi: 10.1097/00042737-200403000-00002. Eur J Gastroenterol Hepatol. 2004. PMID: 15195887 Review.
Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry.
Notohardjo JCL, Kuppen MCP, Westgeest HM, van Moorselaar RJA, Mehra N, Coenen JLLM, van Oort IM, de Vos AI, Vervenne WL, van den Bergh ACM, Aben KKH, Somford DM, Bergman AM, Uyl-de Groot CA, Gerritsen WR, van den Eertwegh AJM. Notohardjo JCL, et al. Among authors: vervenne wl. Eur Urol Focus. 2021 Jul;7(4):788-796. doi: 10.1016/j.euf.2020.03.009. Epub 2020 Apr 30. Eur Urol Focus. 2021. PMID: 32362484
The Effect of Using Pazopanib With Food vs. Fasted on Pharmacokinetics, Patient Safety, and Preference (DIET Study).
Lubberman FJE, Gelderblom H, Hamberg P, Vervenne WL, Mulder SF, Jansman FGA, Colbers A, van der Graaf WTA, Burger DM, Luelmo S, Moes DJAR, van Herpen CML, van Erp NP. Lubberman FJE, et al. Among authors: vervenne wl. Clin Pharmacol Ther. 2019 Nov;106(5):1076-1082. doi: 10.1002/cpt.1515. Epub 2019 Jul 9. Clin Pharmacol Ther. 2019. PMID: 31125423 Clinical Trial.
The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure.
Krens SD, Lubberman FJE, van Egmond M, Jansman FGA, Burger DM, Hamberg P, Vervenne WL, Gelderblom H, van der Graaf WTA, Desar IME, van Herpen CML, van Erp NP. Krens SD, et al. Among authors: vervenne wl. Int J Cancer. 2021 Jun 1;148(11):2799-2806. doi: 10.1002/ijc.33469. Epub 2021 Jan 19. Int J Cancer. 2021. PMID: 33428771 Free PMC article.
A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial.
Bouman-Wammes EW, van den Berg HP, de Munck L, Beeker A, Smorenburg CH, Vervenne WL, Coenen JLLM, Verheul HMW, Gerritsen WR, Van den Eertwegh AJM. Bouman-Wammes EW, et al. Among authors: vervenne wl. Eur J Cancer. 2018 Feb;90:1-9. doi: 10.1016/j.ejca.2017.11.021. Epub 2017 Dec 18. Eur J Cancer. 2018. PMID: 29268139 Clinical Trial.
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.
Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, Safran H, Humblet Y, Perez Ruixo J, Ma Y, Von Hoff D. Van Cutsem E, et al. Among authors: vervenne wl. J Clin Oncol. 2004 Apr 15;22(8):1430-8. doi: 10.1200/JCO.2004.10.112. J Clin Oncol. 2004. PMID: 15084616 Clinical Trial.
21 results